Essen, Germany. Evonik and Cubicure, a spin-off company of Vienna University of Technology, have entered into a cooperative agreement to jointly develop innovative radiation-curing resin systems. The partnership with the start-up company is managed by Creavis, the strategic innovation unit of the specialty chemicals group.

“The Hot Lithography technology developed by Cubicure is an interesting option for manufacturing components that meet the exacting standards of industrial applications,” says Prof. Stefan Buchholz, the executive director of Evonik Creavis GmbH. “We have been using this platform for the development of next-generation radiation-curing resin systems for a while. For this purpose, we are developing custom-made components such as oligomers, specialty monomers and suitable additives.”

In contrast to conventional stereolithography, Hot Lithography generates objects from a shapeless fluid at higher processing temperatures, using laser-induced polymerization. The approach allows for much greater variability for the components to be processed and enables novel material concepts for manufacturing industrial parts. “Evonik is an outstanding cooperation partner that will accompany and support us in our efforts to create stable and scalable additive production processes,” comments Dr. Robert Gmeiner, CEO of Cubicure.

The development work involving radiation-curing resin systems is part of Evonik’s Additive Manufacturing innovation growth field, in which the company is pooling its 3D printing competencies. “Our strategic focus is on developing and manufacturing ‘ready-to-use’ high-performance materials for all relevant 3D printing technologies. Close cooperation with our customers and partners is a prerequisite for advancing innovations,” explains Thomas Große-Puppendahl, the head of the innovation growth field.

Evonik’s research work on radiation-curing resin systems for additive manufacturing will be on display at the “formnext” tradeshow in Frankfurt/Main in Hall 12.1, Stand C71 from November 19 to 22, 2019.

Company information 

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.

To know more about Evonik Middle East and Africa, please visit https://mea.evonik.com/  

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.